6533b820fe1ef96bd1279a0b

RESEARCH PRODUCT

Prophylaxis of hemicrania continua: two new cases effectively treated with topiramate.

Giuseppe CosentinoBrigida FierroAntonio PalermoFilippo Brighina

subject

DrugTopiramateAdultmedia_common.quotation_subjectmedicine.medical_treatmentIndomethacinNeurological disorderFructoseCentral nervous system diseaseDrug withdrawalPrimary headacheTopiramateProfilaxismedicineHumansmedia_commonbusiness.industryAnti-Inflammatory Agents Non-SteroidalHeadacheHemicrania continuaMiddle Agedmedicine.diseaseAnticonvulsantNeurologyHemicrania continuaAnesthesiaGastritisRetreatmentSettore MED/26 - NeurologiaAnticonvulsantsFemaleNeurology (clinical)businessmedicine.drug

description

Hemicrania continua (HC) is an uncommon and under-recognized primary headache disorder characterized by a strictly unilateral continuous headache of moderate intensity with possible exacerbations and associated with ipsilateral autonomic features. HC has generally a prompt and enduring response to indomethacin although 25% to 50% of treated patients develop gastrointestinal side effects. These cases pose a difficult management challenge as no other drug is consistently effective in HC. Recently 2 HC patients responsive to topiramate treatment have been reported. Here we describe 2 more patients effectively treated with topiramate. Neither reported any side effects and one had persisting response for 6 months after drug withdrawal.

yearjournalcountryeditionlanguage
2007-03-21Headache
10.1111/j.1526-4610.2007.00733.xhttps://pubmed.ncbi.nlm.nih.gov/17371364